Evolving concepts and use of immunohistochemical biomarkers in flat non-neoplastic urothelial lesions: WHO 2016 classification update with diagnostic algorithm

References

• Abdel Raheem, S., et al., 2014. The role of CK20, p53 and p63 in differentiation of some urothelial lesions of urinary bladder, immunohistochemical study. Open journal of pathology, 4, 181–193.
   Google Scholar
• Alvoy, J., and Gould, V.E., 1980. Epithelial-stromal interface in normal and neoplastic human bladder epithelium. Ultrastructural pathology, 1, 201–210.
   PubMed Web of Science ®Google Scholar
• Amin, M.B., and Young, R.H., 1997. Intraepithelial lesions of the urinary bladder with a discussion of the histogenesis of urothelial neoplasia. Seminars in diagnostic pathology, 14, 84–97.
   PubMed Web of Science ®Google Scholar
• Amin, M.B., Grignon, D.J., and Eble, J.N., 1997. Intraepithelial lesions of the urothelium: an interobserver reproducibility study with proposed terminology and histologic criteria. Modern pathology, 10, 69.
   Google Scholar
• Amin, M.B., and McKenney, J.K., 2002. An approach to the diagnosis of flat intraepithelial lesions of the urinary bladder using the World Health Organization/International Society of Urological Pathology Consensus Classification System. Advances in anatomic pathology, 9, 222–232.
   PubMed Web of Science ®Google Scholar
• Amin, M.B., Members of the ISUP Immunohistochemistry in Diagnostic Urologic Pathology Group., et al., 2014. Best practices recommendations in the application of immunohistochemistry in the bladder lesions report from the International Society of Urologic Pathology Consensus Conference. The American journal of surgical pathology, 38, e20–e34.
   PubMed Web of Science ®Google Scholar
• Aron, M., et al., 2013. Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20/CD44s/p53) and α-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia. The American journal of surgical pathology, 37, 1815–1823.
   PubMed Web of Science ®Google Scholar
• Baithun, S.I., et al., 2001. Molecular and kinetic features of transitional cell carcinomas of the bladder: biological and clinical implications. Virchows archives, 438, 289–297.
   PubMed Web of Science ®Google Scholar
• Banerjee, S.K., and Lopez-Beltran, A., 2008. Urothelial dysplasia and its mimics. Pathology case reviews, 13, 149–153.
   Google Scholar
• Baud, E., et al., 1998. Human bladder cancers and normal bladder mucosa present the same hot spot of heterozygous chromosome-9 deletion. International journal of cancer, 77, 821–824.
   PubMed Web of Science ®Google Scholar
• Brimo, F., and Epstein, J.I., 2012. Selected common diagnostic problems in urologic pathology. Perspectives from a large consult service in genitourinary pathology. Archives of pathology & laboratory medicine, 136, 360–371.
   PubMed Web of Science ®Google Scholar
• Brunner, A., et al., 2008. Chromosomal aberrations in urothelial carcinoma of the bladder and the World Health Organization 2004 grading system. Analytical and quantitative cytology and histology, 30, 297–305.
   PubMedGoogle Scholar
• Cheng, L., et al., 2000. Flat intraepithelial lesions of the urinary bladder. Cancer, 88, 625–631.
   PubMed Web of Science ®Google Scholar
• Cheng, L., et al., 2011. Bladder cancer: translating molecular genetic insights into clinical practice. Human pathology, 42, 455–481.
   PubMed Web of Science ®Google Scholar
• Cheng, L., et al., 2013. Pathology of flat bladder lesions with emphasis on putative precursors. Diagnostic histopathology, 19, 355–365.
   Google Scholar
• Chow, N., et al., 1997. Expression patterns of erbB receptor family in normal urothelium and transitional cell carcinoma. An immunohistochemical study. Virchows archives, 430, 461–466.
   PubMed Web of Science ®Google Scholar
• Cina, S.J., et al., 2001. Correlation of Ki-67 and p53 with the new World Health Organization/International Society of Urological Pathology Classification System for Urothelial Neoplasia. Archives of pathology & laboratory medicine, 125, 646–651.
   PubMed Web of Science ®Google Scholar
• Compérat, E., et al., 2009. Fluorescence diagnosis and flat lesions of urothelium: new challenges for pathologists and urologists (Review). Oncology reports, 21, 839–844.
   PubMed Web of Science ®Google Scholar
• Czerniak, B., et al., 2000. Genetic modeling of human urinary bladder carcinogenesis. Genes, chromosomes and cancer, 27, 392–402.
   PubMed Web of Science ®Google Scholar
• Dalbagni, G., et al., 1993. Molecular genetic alterations of chromosome 17 and p53 nuclear overexpression in human bladder cancer. Diagnostic molecular pathology, 2, 4–13.
   PubMed Web of Science ®Google Scholar
• Desai, S., et al., 2000. Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia. Modern pathology, 13, 1315–1323.
   PubMed Web of Science ®Google Scholar
• Edgecombe, A., et al., 2012. Utility of cytokeratin 5/6, cytokeratin 20, and p16 in the diagnosis of reactive urothelial atypia and noninvasive component of urothelial neoplasia. Applied immunohistochemistry & molecular morphology, 20, 264–271.
   Web of Science ®Google Scholar
• Emerson, R.E., and Cheng, L., 2005. Immunohistochemical markers in the evaluation of tumors of the urinary bladder: a review. Analytical and quantitative cytology and histology, 27, 301–316.
   PubMedGoogle Scholar
• Epstein, I.J., et al., 1998. The World Health Organisation/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. The American journal of surgical pathology, 22, 1435–1448.
   PubMed Web of Science ®Google Scholar
• Epstein, J.I., 2010. Diagnosis and classification of flat, papillary, and invasive urothelial carcinoma: the WHO/ISUP consensus. International journal of surgical pathology, 18, 106S–111S.
   PubMed Web of Science ®Google Scholar
• Finlay, C.A., et al., 1988. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Molecular and cellular biology, 8, 531–539.
   PubMed Web of Science ®Google Scholar
• Grignon, D.J., 2009. The current classification of urothelial neoplasms. Modern pathology, 22, S60–S69.
   PubMed Web of Science ®Google Scholar
• Grossman, H.B., et al., 2000. Use of markers in defining urothelial premalignant and malignant conditions. Scandinavian journal of urology and nephrology supplementum, 205, 94–104.
   Google Scholar
• Gunia, S., et al., 2011a. Different HER2 protein expression profiles aid in the histologic differential diagnosis between urothelial carcinoma in situ (CIS) and non-CIS conditions (dysplasia and reactive atypia) of the urinary bladder mucosa. The American journal of clinical pathology, 136, 881–888.
   PubMed Web of Science ®Google Scholar
• Gunia, S., et al., 2011b. Lewis y antigen (blood group 8, BG8) is a useful marker in the histopathological differential diagnosis of flat urothelial lesions of the urinary bladder. Journal of clinical pathology, 64, 672–676.
   PubMed Web of Science ®Google Scholar
• Gunia, S., et al., 2012. Scoring the percentage of Ki67 positive nuclei is superior to mitotic count and the mitosis marker phosphohistone H3 (PHH3) in terms of differentiating flat lesions of the bladder mucosa. Journal of clinical pathology, 65, 715–720.
   PubMed Web of Science ®Google Scholar
• Hameed, O., and Humphrey, P.A., 2010. Pseudoneoplastic mimics of prostate and bladder carcinomas. Archives of pathology & laboratory medicine, 134, 427–443.
   PubMed Web of Science ®Google Scholar
• Harik, L.R., and O’Toole, K.M., 2012. Nonneoplastic lesions of the prostate and bladder. Archives of pathology & laboratory medicine, 136, 721–734.
   PubMed Web of Science ®Google Scholar
• Harnden, P., et al., 1996. Cytokeratin 20 as an objective marker of urothelial dysplasia. British journal of urology, 78, 870–875.
   PubMedGoogle Scholar
• Harnden, P., Mahmood, N., and Southgate, J., 1999. Expression of cytokeratin 20 redefines urothelial papillomas of the bladder. Lancet, 353, 974–977.
   PubMed Web of Science ®Google Scholar
• Hartmann, A., et al., 2002. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer research, 62, 809–818.
   PubMed Web of Science ®Google Scholar
• Helpap, B., and Koellermann, J., 2000. Assessment of basal cell status and proliferative patterns in flat and papillary urothelial lesions: a contribution to the new WHO classification of urothelial tumors of the urinary bladder. Human pathology, 31, 745–750.
   PubMed Web of Science ®Google Scholar
• Hodges, K.B., et al., 2010a. Urothelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features. Human pathology, 41, 155–162.
   PubMed Web of Science ®Google Scholar
• Hodges, K.B., et al., 2010b. Clinical utility of immunohistochemistry in the diagnoses of urinary bladder neoplasia. Applied immunohistochemistry & molecular morphology, 18, 401–410.
   Web of Science ®Google Scholar
• Hofmann, T., et al., 2006. Clinical implications of the 2004 WHO histological classification on non-invasive tumours of the urinary bladder. EAU-EBU update series, 4, 83–95.
   Google Scholar
• Humphrey, P.A., et al., 2016. The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours. European urology, 70, 106–119.
   PubMed Web of Science ®Google Scholar
• Hungerhuber, E., et al., 2007. Seven years' experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder. Urology, 69, 260–264.
   PubMed Web of Science ®Google Scholar
• Jost, S.P., Gosling, J.A., and Dixon, J.S., 1989. The morphology of normal human bladder urothelium. Journal of anatomy, 167, 103–115.
   PubMed Web of Science ®Google Scholar
• Jung, S., et al., 2014. The role of immunohistochemistry in the diagnosis of flat urothelial lesions: a study using CK20, CK5/6, P53, Cd138, and Her2/Neu. Annals of diagnostic pathology, 18, 27–32.
   PubMed Web of Science ®Google Scholar
• Kiemeney, L., et al., 1994. Dysplasia in normal-looking urothelium increases the risk of tumour progression in primary superficial bladder cancer. European journal of cancer, 30A, 1621–1625.
   PubMed Web of Science ®Google Scholar
• Kilicli-Camur, N., et al., 2002. Impact of p53 and Ki-67 in predicting recurrence and progression of superficial (pTa and pT1) urothelial cell carcinomas of urinary bladder. Pathology international, 52, 463–469.
   PubMed Web of Science ®Google Scholar
• Koss, L., 1975. Tumors of the urinary bladder: Atlas of tumor pathology (Second Series, fascicle 11). Washington, DC: Armed Forces Institute of Pathology.
   Google Scholar
• Kunju, L.P., et al., 2005. Utility of cytokeratin 20 and Ki-67 as markers of urothelial dysplasia. Pathology international, 55, 248–254.
   PubMed Web of Science ®Google Scholar
• Lawless, M.E., et al., 2016. Flat urothelial lesions with atypia: interobserver concordance and added value of immunohistochemical profiling. Applied immunohistochemistry & molecular morphology, [Epub ahead of print]. DOI:10.1097/PAI.0000000000000401.
   Web of Science ®Google Scholar
• Li, B., et al., 1998. Reciprocal expression of bcl2 and p53 oncoproteins in urothelial dysplasia and carcinoma of the urinary bladder. Urological research, 26, 235–241.
   PubMedGoogle Scholar
• Limas, C., 1993. Proliferative state of the urothelium with benign and atypical changes. Correlation with transferring and epidermal growth factor receptors and blood group antigens. The journal of pathology, 171, 39–47.
   PubMed Web of Science ®Google Scholar
• Liu, F., and Xu, Y., 2011. P53, oxidative stress, and aging. Antioxidants & redox signaling, 15, 1669–1678.
   PubMed Web of Science ®Google Scholar
• Lopez-Beltran, A., et al., 2002a. Preneoplastic nonpapillary lesions and conditions of the urinary bladder: an update based on the Ancona International Consultation. Virchows archives, 440, 3–11.
   PubMed Web of Science ®Google Scholar
• Lopez-Beltran, A., et al., 2002b. Changes produced in the urothelium by traditional and newer therapeutic procedures for bladder cancer. Journal of clinical pathology, 55, 641–647.
   PubMed Web of Science ®Google Scholar
• Lopez-Beltran, A., and Montironi, R., 2004. Non-invasive urothelial neoplasms: according to the most recent WHO classification. European urology, 46, 170–176.
   PubMed Web of Science ®Google Scholar
• Lopez-Beltran, A., et al., 2013. Urothelial dysplasia of the bladder diagnostic features and clinical significance. Analytical and quantitative cytology and histology, 35, 121–129.
   Google Scholar
• Lopez-Beltran, A., et al., 2015. Dysplasia and carcinoma in situ of the urinary bladder. Analytical and quantitative cytology and histology, 37, 29–38.
   Web of Science ®Google Scholar
• Mallofre, C., et al., 2003. Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia. Modern pathology, 16, 187–191.
   PubMed Web of Science ®Google Scholar
• Mazzucchelli, R., et al., 2005. Chromosomal abnormalities in macroscopically normal urothelium in patients with bladder pT1 and pT2a urothelial carcinoma: a fluorescence in situ hybridization study and correlation with histologic features. Analytical and quantitative cytology and histology, 27, 143–151.
   PubMedGoogle Scholar
• McKenney, J.K., et al., 2001. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens. American journal of surgical pathology, 25, 1074–1078.
   PubMed Web of Science ®Google Scholar
• McKenney, J.K., and Amin, M.B., 2005. The role of immunohistochemistry in the diagnosis of urinary bladder neoplasms. Seminars in diagnostic pathology, 22, 69–87.
   PubMed Web of Science ®Google Scholar
• Moch, H., et al., 1993. p53 and erbB-2 protein overexpression are associated with early invasion and metastasis in bladder cancer. Virchows archives A pathological anatomy and histopathology, 423, 329–334.
   PubMedGoogle Scholar
• Montironi, R., et al., 2003a. Classification and grading of the non-invasive urothelial neoplasms: recent advances and controversies. Journal of clinical pathology, 56, 91–95.
   PubMed Web of Science ®Google Scholar
• Montironi, R., and Mazzucchelli, R., 2003. Preneoplastic lesions and conditions of the urinary bladder. EAU update series, 1, 53–63.
   Google Scholar
• Montironi, R., et al., 2003b. Subvisual changes in chromatin organization state are detected by karyometry in the histologically normal urothelium in patients with synchronous papillary carcinoma. Human pathology, 34, 893–901.
   PubMed Web of Science ®Google Scholar
• Montironi, R., and Lopez-Beltran, A., 2005. The 2004 WHO Classification of bladder tumors: a summary and commentary. International journal of surgical pathology, 13, 143–153.
   PubMed Web of Science ®Google Scholar
• Montironi, R., et al., 2008a. Morphological diagnosis of urothelial neoplasms. Journal of clinical pathology, 61, 3–10.
   PubMed Web of Science ®Google Scholar
• Montironi, R., et al., 2008b. Morphological classification and definition of the benign, preneoplastic and non-invasive neoplastic lesions of the urinary bladder. Histopathology, 53, 621–633.
   PubMed Web of Science ®Google Scholar
• Montironi, R., et al., 2011. How much do you know about benign, preneoplastic, non-invasive and invasive neoplastic lesions of the urinary bladder classified according to the 2004 WHO scheme? Diagnostic pathology, 6, 31–39.
   PubMed Web of Science ®Google Scholar
• Mostofi, F. K., Sobin, L. H., and Torloni, H., 1973. Histological typing of urinary bladder tumours. Geneva: World Health Organization.
   Google Scholar
• Murata, S., et al., 2010. Molecular and immunohistologic analyses cannot reliably solve diagnostic variation of flat intraepithelial lesions of the urinary bladder. American journal of clinical pathology, 134, 862–872.
   PubMed Web of Science ®Google Scholar
• Murphy, W. M., Beckwith, J. B., and Farrow, G. M., 1994. Tumors of the kidney, bladder and related urinary structures (Third Series, fascicle 11). Washington, DC: Armed Forces Institute of Pathology.
   Google Scholar
• Nagy, G. K., Frable, W. J., and Murphy, W. M., 1982. The classification of premalignant urothelial abnormalities: a Delphi study of the National Bladder Clinical Collaborative Group A. In: S.C. Sommer and P.P. Rosen, eds. Pathology annual (Vol 17). Norwalk, CT: Appleton-Century-Crofts, 219–233.
   Google Scholar
• Nakazawa, K., et al., 2009. p16INK4a expression analysis as an ancillary tool for cytologic diagnosis of urothelial carcinoma. American Journal of Clinical Pathology, 132, 776–784.
   PubMed Web of Science ®Google Scholar
• Obermann, E.C., et al., 2003. Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses. The journal of pathology, 199, 50–57.
   PubMed Web of Science ®Google Scholar
• Olumi, A., et al., 1990. Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder. Cancer research, 50, 7081–7083.
   PubMed Web of Science ®Google Scholar
• Petraki, C.D., and Sfikas, C.P., 2008. Non-papillary urothelial lesions of the urinary bladder: morphological classification and immunohistochemical markers. In Vivo, 22, 493–502.
   PubMed Web of Science ®Google Scholar
• Poropatich, K., et al., 2016. Nuclear size measurement for distinguishing urothelial carcinomas from reactive urothelium on tissue sections. Diagnostic pathology, 11, 57.
   PubMed Web of Science ®Google Scholar
• Readal, N., and Epstein, J.I., 2010. Papillary urothelial hyperplasia: relationship to urothelial neoplasms. Pathology, 42, 360–363.
   PubMed Web of Science ®Google Scholar
• Requena, M.J., Alvarez-Kindelan, J., and Blanca, A., 2007. Immunohistochemical markers in the evaluation of tumors of the urinary bladder: a review. Analytical and quantitative cytology and histology, 29, 380–382.
   PubMedGoogle Scholar
• Reuter, V.E., et al., 2016. Non-invasive urothelial lesions. In: H. Moch, P.A. Humphrey, T.M. Ulbright, V.E. Reuter, eds. WHO classification of tumours of the urinary system and male genital organs. Lyon: IARC.
   Google Scholar
• Sanfrancesco, J., Jones, J.S., and Hansel, D.E., 2013. Diagnostically challenging cases: what are atypia and dysplasia? Urologic clinics of North America, 40, 281–293.
   PubMed Web of Science ®Google Scholar
• Schwarz, S., et al., 2008. Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions. Journal of clinical pathology, 61, 272–277.
   PubMed Web of Science ®Google Scholar
• Shimada, K., et al., 2010. Role of syndecan-1 (CD138) in cell survival of human urothelial carcinoma. Cancer science, 101, 155–160.
   PubMed Web of Science ®Google Scholar
• Simon, R., et al., 2003. HER-2 and TOP2A coamplification in urinary bladder cancer. International journal of cancer, 107, 764–772.
   PubMed Web of Science ®Google Scholar
• Soloway, M., Carmack, A., and Khoury, S., 2005. Bladder tumors. Paris: Health Publications Ltd.
   Google Scholar
• Stadler, W.M., et al., 2001. Alterations of the 9p21 and 9q33 chromosomal bands in clinical bladder cancer specimens by fluorescence in situ hybridization. Clinical cancer research, 7, 1676–1682.
   PubMed Web of Science ®Google Scholar
• Steinestel, J., et al., 2013. Overexpression of p16(INK4a) in urothelial carcinoma in situ is a marker for MAPK-mediated epithelial-mesenchymal transition but is not related to human Papillomavirus infection. PLoS one, 8, e65189.
   PubMed Web of Science ®Google Scholar
• Taylor, D.C., et al., 1996. Papillary urothelial hyperplasia. A precursor to papillary neoplasms. American journal of surgical pathology, 20, 1481–1488.
   PubMed Web of Science ®Google Scholar
• van Oers, J.M.M., et al., 2006. Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder. International journal of cancer, 119, 1212–1215.
   PubMed Web of Science ®Google Scholar
• Wagner, U., et al., 1995. Patterns of p53, erbB-2, and EGF-r expression in premalignant lesions of the urinary bladder. Human pathology, 26, 970–978.
   PubMed Web of Science ®Google Scholar
• Wilkerson, M.L., et al., 2014. The application of immunohistochemical biomarkers in urologic surgical pathology. Archives of pathology & laboratory medicine, 138, 1643–1665.
   PubMed Web of Science ®Google Scholar
• Wright, C., et al., 1991. Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. British journal of cancer, 63, 967–970.
   PubMed Web of Science ®Google Scholar
• Xiao, X., et al., 2017. Practical Applications of Immunohistochemistry in the Diagnosis of Genitourinary Tumors. Archives of pathology & laboratory medicine, 141, 1181–1194.
   PubMed Web of Science ®Google Scholar
• Yildiz, I.Z., et al., 2009. Utility of a dual immunostain cocktail comprising of p53 and CK20 to aid in the diagnosis of non-neoplastic and neoplastic bladder biopsies. Diagnostic pathology, 14, 35.
   Google Scholar
• Yin, H., and Leong, A.S., 2004. Histologic grading of noninvasive papillary urothelial tumors: validation of the 1998 WHO/ISUP system by immunophenotyping and follow-up. American journal of clinical pathology, 121, 679–687.
   PubMed Web of Science ®Google Scholar
• Yin, H., et al., 2006. Cytokeratin 20 and Ki-67 to distinguish carcinoma in situ from flat non-neoplastic urothelium. Applied immunohistochemistry & molecular morphology, 14, 260–265.
   Web of Science ®Google Scholar
• Yin, M., et al., 2008. p16ink4 immunoreactivity is a reliable marker for urothelial carcinoma in situ. Human pathology, 39, 527–535.
   PubMed Web of Science ®Google Scholar